Binding features of steroidal and nonsteroidal inhibitors

Steroids

Volumn 76, Issue 8, 2011, Pages 802-806

  Hong, Yanyan ^a   Rashid, Rumana ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Androstenedione; Aromatase; Exemestane; Letrozole; Site directed mutagenesis

Indexed keywords

AMINO ACID; ANASTROZOLE; ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 REDUCTASE; EXEMESTANE; HEME; LETROZOLE; MUTANT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; TRIAZOLE;

CATALYSIS; CONFERENCE PAPER; DNA HELIX; DRUG BINDING; DRUG DNA BINDING; DRUG MECHANISM; ENZYME ACTIVITY; IC 50; KINETICS; MOLECULAR DOCKING; MUTAGENESIS; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; STEROID BINDING; WESTERN BLOTTING; WILD TYPE;

AMINO ACIDS; ANDROGENS; ANDROSTADIENES; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITORS; BINDING SITES; BREAST NEOPLASMS; CATALYTIC DOMAIN; ESTROGENS; ESTRONE; FEMALE; HUMANS; MUTAGENESIS, SITE-DIRECTED; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 79958767072     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.037     Document Type: Conference Paper

References (21)

1. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA 1997;94:8411-6. (Pubitemid 27335052)
2. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009;457: 219-23.
3. Hong Y, Li H, Ye J, Miki Y, Yuan YC, Sasano H, et al. Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity. PLoS One 2009;4:e8050.
4. Chen S, Aromatase, breast cancer. Front Biosci 1998;3:d922-33.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. (Pubitemid 38298988)
6. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359: 2131-9. (Pubitemid 34694019)
7. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92. (Pubitemid 350002953)
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. (Pubitemid 37362955)
9. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
10. Chen S, Masri S, Hong Y, Wang X, Phung S, Yuan YC, et al. New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 2007;106:8-15. (Pubitemid 47362647)
11. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 2007;21:401-14. (Pubitemid 46184893)
12. Kao YC, Cam LL, Laughton CA, Zhou D, Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996;56:3451-60. (Pubitemid 26251636)
13. Sevrioukova IF, Li H, Zhang H, Peterson JA, Poulos TL. Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci USA 1999;96:18638.
14. Bernhardt R, Kraft R, Otto A, Ruckpaul K. Electrostatic interactions between cytochrome P-450 LM2 and NADPH-cytochrome P-450 reductase. Biomed Biochim Acta 1988;47:581-92.
15. Shimizu T, Tateishi T, Hatano M, Fujii-Kuriyama Y. Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J BiolChem 1991;266:3372-5. (Pubitemid 21909220)
16. Stayton PS, Sligar SG. The cytochrome P-450cam binding surface as defined by site-directed mutagenesis and electrostatic modeling. Biochemistry 1990;29:7381-6. (Pubitemid 20251786)
17. Kao YC, Korzekwa KR, Laughton CA, Chen S. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur J Biochem 2001;268:243-51. (Pubitemid 32867307)
18. Kadohama N, Yarborough C, Zhou D, Chen S, Osawa Y. Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors. J Steroid Biochem Mol Biol 1992;43:693-701. (Pubitemid 23002502)
19. Zhou DJ, Korzekwa KR, Poulos T, Chen SA. A site-directed mutagenesis study of human placental aromatase. J Biol Chem 1992;267:762-8.
20. Ghosh D, Griswold J, Erman M, Pangborn W. X-ray structure of human aromatase reveals an androgen-specific active site. J Steroid Biochem Mol Biol 2010;118:197-202.
21. Hong Y, Li H, Yuan YC, Chen S. Molecular characterization of aromatase. Ann N Y Acad Sci 2009;1155:112-20.